Literature DB >> 33290688

Meta-analysis of the Usefulness of Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure With Preserved Ejection Fraction.

Omar M Aldaas1, Florentino Lupercio1, Douglas Darden1, Praneet S Mylavarapu1, Chaitanya L Malladi1, Frederick T Han1, Kurt S Hoffmayer1, David Krummen1, Gordon Ho1, Farshad Raissi1, Ulrika Birgersdotter-Green1, Gregory K Feld1, Jonathan C Hsu2.   

Abstract

Catheter ablation improves clinical outcomes in atrial fibrillation (AF) patients with heart failure (HF) with reduced ejection fraction (HFrEF). However, the role of catheter ablation in HF with a preserved ejection fraction (HFpEF) is less clear. We performed a literature search and systematic review of studies that compared AF recurrence at one year after catheter ablation of AF in patients with HFpEF versus those with HFrEF. Risk ratio (RR; where a RR <1.0 favors the HFpEF group) and mean difference (MD; where MD <0 favors the HFpEF group) 95% confidence intervals (CI) were measured for dichotomous and continuous variables, respectively. Six studies with a total of 1,505 patients were included, of which 764 (51%) had HFpEF and 741 (49%) had HFrEF. Patients with HFpEF experienced similar recurrence of AF 1 year after ablation on or off antiarrhythmic drugs compared with those with HFrEF (RR 1.01; 95% CI 0.76, 1.35). Fluoroscopy time was significantly shorter in the HFpEF group (MD -5.42; 95% CI -8.51, -2.34), but there was no significant difference in procedure time (MD 1.74; 95% CI -11.89, 15.37) or periprocedural adverse events between groups (RR 0.84; 95% CI 0.54,1.32). There was no significant difference in hospitalizations between groups (MD 1.18; 95% CI 0.90, 1.55), but HFpEF patients experienced significantly less mortality (MD 0.41; 95% CI 0.18, 0.94). In conclusion, based on the results of this meta-analysis, catheter ablation of AF in patients with HFpEF appears as safe and efficacious in maintaining sinus rhythm as in those with HFrEF.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 33290688      PMCID: PMC7902199          DOI: 10.1016/j.amjcard.2020.11.039

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  40 in total

1.  Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.

Authors:  Ulrik Sartipy; Ulf Dahlström; Michael Fu; Lars H Lund
Journal:  JACC Heart Fail       Date:  2017-07-12       Impact factor: 12.035

2.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  Ann Intern Med       Date:  2009-07-20       Impact factor: 25.391

3.  Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of get with the guidelines-heart failure.

Authors:  Stavros E Mountantonakis; Maria V Grau-Sepulveda; Deepak L Bhatt; Adrian F Hernandez; Eric D Peterson; Gregg C Fonarow
Journal:  Circ Heart Fail       Date:  2012-02-23       Impact factor: 8.790

4.  Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction.

Authors:  Eric Black-Maier; Xinru Ren; Benjamin A Steinberg; Cynthia L Green; Adam S Barnett; Normita Sta Rosa; Sana M Al-Khatib; Brett D Atwater; James P Daubert; Camille Frazier-Mills; Augustus O Grant; Donald D Hegland; Kevin P Jackson; Larry R Jackson; Jason I Koontz; Robert K Lewis; Albert Y Sun; Kevin L Thomas; Tristam D Bahnson; Jonathan P Piccini
Journal:  Heart Rhythm       Date:  2017-12-06       Impact factor: 6.343

5.  Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.

Authors:  Lars G Olsson; Karl Swedberg; Anique Ducharme; Christopher B Granger; Eric L Michelson; John J V McMurray; Margareta Puu; Salim Yusuf; Marc A Pfeffer
Journal:  J Am Coll Cardiol       Date:  2006-04-27       Impact factor: 24.094

6.  Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007.

Authors:  Jonathan P Piccini; Bradley G Hammill; Moritz F Sinner; Paul N Jensen; Adrian F Hernandez; Susan R Heckbert; Emelia J Benjamin; Lesley H Curtis
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-01-10

7.  Atrial fibrillation ablation strategies and outcome in patients with heart failure: insights from the German ablation registry.

Authors:  Charlotte Eitel; Hueseyin Ince; Johannes Brachmann; Karl-Heinz Kuck; Stephan Willems; Jin-Hong Gerds-Li; Juergen Tebbenjohanns; Gert Richardt; Matthias Hochadel; Jochen Senges; Roland R Tilz
Journal:  Clin Res Cardiol       Date:  2019-02-20       Impact factor: 5.460

Review 8.  Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target.

Authors:  David R Van Wagoner
Journal:  J Cardiovasc Pharmacol       Date:  2008-10       Impact factor: 3.105

9.  Impact of catheter ablation of atrial fibrillation on long-term clinical outcomes in patients with heart failure.

Authors:  Sadamitsu Ichijo; Shinsuke Miyazaki; Shigeki Kusa; Hiroaki Nakamura; Hitoshi Hachiya; Takatsugu Kajiyama; Yoshito Iesaka
Journal:  J Cardiol       Date:  2018-03-30       Impact factor: 3.159

Review 10.  Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses.

Authors:  Hugh Calkins; Matthew R Reynolds; Peter Spector; Manu Sondhi; Yingxin Xu; Amber Martin; Catherine J Williams; Isabella Sledge
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-06-02
View more
  6 in total

Review 1.  Management of Atrial Tachyarrhythmias in Heart Failure-an Interventionalist's Point of View.

Authors:  Jason A Gencher; Nathaniel M Hawkins; Marc W Deyell; Jason G Andrade
Journal:  Curr Heart Fail Rep       Date:  2022-03-30

2.  Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction: A meta-analysis.

Authors:  Gaoyang Gu; Jing Wu; Xiaofei Gao; Meijun Liu; Chaolun Jin; Yizhou Xu
Journal:  Clin Cardiol       Date:  2022-05-11       Impact factor: 3.287

3.  Atrial fibrillation in heart failure: Prime time for ablation!

Authors:  Isabel Deisenhofer
Journal:  Heart Rhythm O2       Date:  2021-12-17

4.  Cryoballoon Ablation for the Treatment of Atrial Fibrillation in Patients With Concomitant Heart Failure and Either Reduced or Preserved Left Ventricular Ejection Fraction: Results From the Cryo AF Global Registry.

Authors:  Roberto Rordorf; Fernando Scazzuso; Kyoung Ryul Julian Chun; Surinder Kaur Khelae; Fred J Kueffer; Kendra M Braegelmann; Ken Okumura; Fawzia Al-Kandari; Young Keun On; Csaba Földesi
Journal:  J Am Heart Assoc       Date:  2021-12-10       Impact factor: 5.501

Review 5.  Comorbidities in heart failure with preserved ejection fraction.

Authors:  Andrea Deichl; Rolf Wachter; Frank Edelmann
Journal:  Herz       Date:  2022-06-08       Impact factor: 1.740

6.  Long-Term prognosis of radiofrequency catheter ablation for atrial fibrillation with different subtypes of heart failure in the era of ablation index guidance.

Authors:  Yu Qiao; Zhen Zhao; Xiang Cai; Yulong Guo; Mingpeng Fu; Ke Liu; Jinrui Guo; Tao Guo; Guodong Niu
Journal:  Front Cardiovasc Med       Date:  2022-09-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.